NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
55292-0811-55 | 55292-0811 | Dactinomycin | Cosmegen | 0.5 mg/mL | Chemotherapy | Antitumor Antibiotic | Carboxylic Acids and Amino Acids/Peptides | Intravenous | Dec 10, 1964 | Nov 30, 2024 | No Longer Used |
70934-0809-88 | 70934-0809 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Aug 16, 2021 | Nov 30, 2024 | No Longer Used |
66993-0489-35 | 66993-0489 | Dactinomycin | Dactinomycin | 0.5 mg/mL | Chemotherapy | Antitumor Antibiotic | Carboxylic Acids and Amino Acids/Peptides | Intravenous | Dec 4, 2017 | Nov 30, 2024 | No Longer Used |
54838-0555-50 | 54838-0555 | Ondansetron Hydrochloride | Ondansetron | 4.0 mg/5mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan 27, 2011 | Nov 30, 2024 | No Longer Used |
25021-0231-20 | 25021-0231 | Decitabine | Decitabine | 50.0 mg/10mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Aug 15, 2018 | Nov 30, 2024 | No Longer Used |
70934-0634-89 | 70934-0634 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb 7, 2022 | Nov 30, 2024 | In Use |
70860-0200-17 | 70860-0200 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Mar 24, 2017 | Nov 30, 2024 | No Longer Used |
70860-0215-67 | 70860-0215 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Dec 15, 2021 | Nov 30, 2024 | No Longer Used |
71334-0100-01 | 71334-0100 | Ivosidenib | Tibsovo | 250.0 mg/1 | Chemotherapy | Enzyme Inhibitor | IDH1 | Oral | Jul 20, 2018 | Nov 30, 2024 | No Longer Used |
70518-3512-03 | 70518-3512 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Oct 31, 2023 | Nov 24, 2024 | In Use |
68788-8365-05 | 68788-8365 | Ondansetron Hydrochloride | Ondansetron | 4.0 mg/5mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb 1, 2023 | Nov 1, 2024 | No Longer Used |
69076-0913-02 | 69076-0913 | Mercaptopurine | Mercaptopurine | 50.0 mg/1 | Chemotherapy | Antimetabolite | Purine Analog | Oral | Oct 5, 2016 | Oct 31, 2024 | No Longer Used |
70934-0318-04 | 70934-0318 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jun 11, 2021 | Oct 31, 2024 | No Longer Used |
00078-0670-66 | 00078-0670 | Pazopanib Hydrochloride | Votrient | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FGF, PDGFR, KIT, Lck, FMS | Oral | Jul 12, 2016 | Oct 31, 2024 | No Longer Used |
70860-0218-05 | 70860-0218 | Cyclophosphamide | Cyclophosphamide | 200.0 mg/mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Dec 11, 2020 | Oct 31, 2024 | No Longer Used |
69076-0913-25 | 69076-0913 | Mercaptopurine | Mercaptopurine | 50.0 mg/1 | Chemotherapy | Antimetabolite | Purine Analog | Oral | Oct 5, 2016 | Oct 31, 2024 | No Longer Used |
70934-0318-05 | 70934-0318 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Sep 27, 2021 | Oct 31, 2024 | No Longer Used |
70934-0318-03 | 70934-0318 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Mar 13, 2019 | Oct 31, 2024 | No Longer Used |
70860-0217-10 | 70860-0217 | Arsenic Trioxide | Arsenic Trioxide | 1.0 mg/mL | Chemotherapy | Miscellaneous Agent | PML/RARa | Intravenous | Nov 30, 2020 | Oct 31, 2024 | In Use |
70860-0218-03 | 70860-0218 | Cyclophosphamide | Cyclophosphamide | 200.0 mg/mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Dec 11, 2020 | Oct 31, 2024 | No Longer Used |
70934-0318-06 | 70934-0318 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Sep 1, 2021 | Oct 31, 2024 | No Longer Used |
00310-9501-95 | 00310-9501 | Capivasertib | TRUQAP | 200.0 mg/1 | Chemotherapy | AKT Inhibitor | AKT1/2/3 | Oral | Feb 1, 2024 | Oct 28, 2024 | In Use |
83831-0104-05 | 83831-0104 | Palonosetron | Posfrea | 0.075 mg/1.5mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Sep 30, 2024 | Sep 30, 2024 | No Longer Used |
00781-9253-94 | 00781-9253 | Azacitidine | Azacitidine | 100.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, Subcutaneous | Mar 27, 2014 | Sep 30, 2024 | No Longer Used |
16714-0572-01 | 16714-0572 | Leuprolide acetate | Leuprolide acetate | 5.0 mg/ml | Hormonal Therapy | GnRH Agonist | Subcutaneous | Aug 1, 2022 | Sep 30, 2024 | No Longer Used |
Found 11465 results — Export these results